Tempus AI (NASDAQ:TEM) CAO Ryan Bartolucci Sells 4,116 Shares

Tempus AI, Inc. (NASDAQ:TEM) CAO Ryan Bartolucci sold 4,116 shares of Tempus AI stock in a transaction dated Tuesday, May 19th. The stock was sold at an average price of $44.07, for a total value of $181,392.12. Following the completion of the sale, the chief accounting officer directly owned 74,041 shares of the company’s stock, valued at approximately $3,262,986.87. This trade represents a 5.27% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Tempus AI Stock Performance

TEM traded up $0.61 during trading hours on Thursday, hitting $46.49. The stock had a trading volume of 3,802,434 shares, compared to its average volume of 5,629,236. The company’s fifty day simple moving average is $49.11 and its 200 day simple moving average is $59.69. Tempus AI, Inc. has a 1 year low of $41.73 and a 1 year high of $104.32. The stock has a market cap of $8.35 billion, a PE ratio of -27.03 and a beta of 3.99. The company has a quick ratio of 3.15, a current ratio of 3.31 and a debt-to-equity ratio of 2.96.

Tempus AI (NASDAQ:TEM) last issued its quarterly earnings data on Tuesday, May 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.08. The business had revenue of $348.12 million for the quarter, compared to analysts’ expectations of $345.44 million. Tempus AI had a negative return on equity of 53.83% and a negative net margin of 22.20%.The firm’s quarterly revenue was up 36.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.24) EPS. Equities analysts anticipate that Tempus AI, Inc. will post -1.35 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts recently issued reports on the company. Mizuho assumed coverage on Tempus AI in a report on Thursday, February 19th. They set an “outperform” rating and a $100.00 price objective on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Tempus AI in a report on Thursday, January 22nd. Stifel Nicolaus set a $60.00 price objective on Tempus AI in a report on Wednesday, February 25th. Needham & Company LLC reaffirmed a “buy” rating and issued a $75.00 price target on shares of Tempus AI in a report on Wednesday, March 11th. Finally, Robert W. Baird assumed coverage on Tempus AI in a report on Tuesday, February 17th. They issued an “outperform” rating and a $59.00 price target on the stock. Nine research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, Tempus AI presently has an average rating of “Moderate Buy” and an average target price of $68.64.

Institutional Trading of Tempus AI

Institutional investors and hedge funds have recently modified their holdings of the business. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Tempus AI by 1,459.8% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 101,276 shares of the company’s stock valued at $8,174,000 after acquiring an additional 94,783 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Tempus AI by 22.1% during the 3rd quarter. Vanguard Group Inc. now owns 9,441,607 shares of the company’s stock valued at $762,032,000 after purchasing an additional 1,706,837 shares during the last quarter. Hussman Strategic Advisors Inc. bought a new position in shares of Tempus AI during the 3rd quarter valued at about $1,695,000. Krane Funds Advisors LLC increased its position in shares of Tempus AI by 218.2% during the 3rd quarter. Krane Funds Advisors LLC now owns 28,230 shares of the company’s stock valued at $2,427,000 after purchasing an additional 19,358 shares during the last quarter. Finally, Aberdeen Group plc increased its position in shares of Tempus AI by 64.2% during the 4th quarter. Aberdeen Group plc now owns 263,004 shares of the company’s stock valued at $15,530,000 after purchasing an additional 102,878 shares during the last quarter. Hedge funds and other institutional investors own 24.22% of the company’s stock.

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.